The Food and Drug Administration has approved the monoclonal antibody Vectibix (panitumumab) for the treatment of patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma that has progressed during or after chemotherapy regimens that contain a fluoropyrimidine, oxaliplatin, and/or irinotecan. For more information, contact Amgen Inc. at 800-772-6436.